endostar + docetaxel + cisplatin

This is a combination regimen of three drugs used primarily in the treatment of various cancers: - **Endostar** (recombinant human endostatin) is an anti-angiogenic agent that inhibits tumor blood vessel formation by blocking endothelial cell proliferation and migration. It targets multiple pathways involved in angiogenesis. - **Docetaxel** is a taxane-class small molecule chemotherapeutic that stabilizes microtubules and prevents their depolymerization. This disrupts mitosis and leads to apoptosis in rapidly dividing cancer cells[1][2][5]. - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis by interfering with DNA replication and transcription. The combination of these agents has been investigated for synergistic effects against solid tumors such as non-small cell lung cancer (NSCLC), head and neck cancers, gastric adenocarcinoma, among others[2][3][4][6]. Docetaxel plus cisplatin is an established regimen for NSCLC and other solid tumors; adding Endostar may enhance anti-tumor efficacy through complementary mechanisms.

Other names

recombinant human endostatinEndostar (for recombinant human endostatin)docetaxel anhydrouscis-diamminedichloroplatinum(II)